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were identified. After removing duplicates, 1,525 citations were screened. Of these, 
159 full text references were reviewed and 85 systematic reviews met predefined 
inclusion criteria. Five QA methods were most commonly employed: Newcastle-
Ottawa Quality Assessment Scale (NOS) or modified NOS (28%); checklists devel-
oped by authors (15%); the Cochrane checklist or modified version (11%); modified 
checklists from other authors (5%); applying disease-specific QA tools (5%). The 
reliability and applicability of the most commonly employed tool in this research 
field, NOS, were questioned in included reviews, corresponding with concerns on the 
validity of the NOS reported in recently published literature of research methodol-
ogy. ConClusions: The available evidence demonstrates a lack of consensus on 
the use of QA tools for non-RCTs assessing surgical interventions. Various methods 
have been adapted or newly developed by researchers, and the most commonly 
applied QA tool (NOS) may not be fit for purpose in this field of research. There is 
an urgent need for a validated QA tool to appraise the quality of evidence to help 
inform evidence-based decision making on the use of surgical devices and types 
of surgical approaches.
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IncIdence and PRevalence estIMatIons Based on claIMs data – new 
MethodologIcal consIdeRatIons
Prosser C1, Altevers J1, Hickstein L2, Walker J2, Braun S1
1Xcenda GmbH, Hannover, Germany, 2Elsevier Health Analytics, Health Risk Institute, Berlin, 
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objeCtives: Scientific analyses with claims data such as burden of disease analyses 
are often based on incidence and prevalence estimates. Latest methodological con-
siderations indicate that the diagnosis-free observation period should be extended 
as much as possible to not overestimate the incidence in chronic diseases. Aim of 
this study was to evaluate the impact of expanding the diagnosis timeframe for 
the incidence as well as the prevalence estimates. Methods: This methodologi-
cal analysis focused on the chronic diseases diabetes mellitus (DM) and multiple 
sclerosis (MS) in 2013 in Germany and was based on anonymized data from the 
Health Risk Institute Research Database. Patients continuously insured for six years 
(2008-2013) were included in the study (n= 3,026,154). Incidence changes due to dif-
ferent diagnosis-free intervals before a diagnosis in 2013 (1 to 5 years) were assessed. 
Correspondingly, the prevalence estimation for 2013 was varied by expanding the 
timeframe for diagnosis from 1 year up to 5 years, as it was assumed that chronic 
diseases identified in previous years persist until 2013. Moreover, disease-specific 
validation of the diagnosis codes was applied as sensitivity analysis. Results: DM 
incidence was 24% higher when a 1-year diagnosis-free observation period was 
applied compared to 5 years (25% in MS). When expanding the prevalence timeframe 
up to 5 years, the prevalence estimation increased by 14% in DM and 21% in MS, 
respectively. The relative proportion of incidence to prevalence also changed by 
varying the utilized timeframe. Out of the prevalent diabetes patients in 2013 10.1% 
were incident when a 1-year timeframe was considered, whereas 7.3% were incident 
when 5 years were applied (11.7% and 7.9% in MS, respectively). ConClusions: 
The methodological concepts should coincide when estimating both the incidence 
and the prevalence of chronic diseases in claims data. Estimates may be biased 
especially when only short timeframes are utilized.
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statIstIcal assessMent of a case-fIndIng algoRIthM foR IdentIfyIng 
non-sMall cell lung canceR (nsclc) PatIents In adMInIstRatIve 
claIMs dataBases
Turner RM1, Croft E2, Chen Y1, Tunceli O3, Elesinmogun C2, Fernandes A2
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objeCtives: The ICD-9-CM coding system does not differentiate between small cell 
lung cancers (SCLC) and NSCLC, which poses a challenge for database research on 
forms of lung cancer. We examined the accuracy of an algorithm designed to identify 
likely NSCLC cases among lung cancer patients in a claims-database. Methods: 
Lung cancer patients were selected from the HealthCore Integrated Research 
Environment (HIRE)-Oncology database which combines US administrative claims 
database, and the clinical oncology data (type, stage, etc.) on lung cancer patients. 
Index event was defined as the patient’s first lung cancer diagnosis during 6/1/14 
to 1/31/15 in the claims database. Eligibility criteria were; ≥ 1 lung cancer diagnosis 
& > 12 months continuous pre-index enrolment in the claims database; and pres-
ence in the oncology database. A treatment regimen algorithm was used to iden-
tify NSCLC patients from claims data. This was assessed against the cancer type 
information from the oncology database. Diagnostic accuracy of the algorithm was 
assessed using statistical measures; Sensitivity, Specificity, False Positive Fraction 
(FPF), Positive Predictive Validity (PPV), Negative Predictive Validity (NPV), Positive 
Likelihood Ratio (LR+), Negative Likelihood Ratio (LR-), Diagnostic Odds Ratio (DOR), 
and Agreement (kappa:k). Results: 585 lung cancer patients (mean age = 62, 53% 
male) met all eligibility criteria for analysis. The algorithm classified 464 (79%) 
patients as NSCLC and 121 (21%) as SCLC; whereas, the clinical data classified 513 
(88%) patients as NSCLC and 72 (12%) as SCLC. Algorithm sensitivity was 86% and 
specificity was 71%. The FPF = .29%, PPV= 96%, and NPV= 42%. LR+ = 2.96; LR- = 0.19; 
and DOR= 15.37. Chance adjusted k = .60. ConClusions: The algorithm showed 
good statistical properties for identifying NSCLC patients in claims data except 
for a high false positive fraction. Future research should focus on improving the 
algorithm’s specificity.
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systeMatIc lIteRatuRe RevIew of adjunctIve antI-ePIlePtIc dRug 
tRIals In PatIents wIth PRIMaRy geneRalIzed tonIc-clonIc seIzuRes 
IllustRates changes In standaRd of caRe oveR 12-20 yeaRs
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lowed in the majority of manufacturer submissions where supplementary searches 
were conducted. However, the results from this study are limited due to the low 
number of appendices published online. Supplementary search methods used in 
manufacturer submissions should be reported in full and ERGs should be consist-
ent with critique of supplementary search methodology to ensure no evidence is 
omitted in decision making.
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IncReasIng PRecIsIon of Real-woRld data estIMates: the IMPoRtance 
of a steP-wIse PRocess to lIMIt data collectIon eRRoRs and data 
IncoMPleteness
Kritikou P1, de Cock E2, Stein D3
1United BioSource Corporation, London, UK, 2UBC: An Express Scripts Company, London, UK, 
3UBC: An Express Scripts Company, Dorval, QC, Canada
objeCtives: Create a step-wise process to mitigate data collection errors and miss-
ing data during all phases of prospective and retrospective observational stud-
ies. Methods: Based on three multinational retrospective chart review studies 
and two multinational time and motion (T&M) studies completed in 2015, key fac-
tors were identified during all study phases (design, implementation, conduct, and 
analysis) that could lead to data collection errors and missing data. For both meth-
odologies, we designed a step-wise process to help identify risk factors and provide 
effective solutions to improve data quality. Results: During study design, study 
variables should unequivocally be defined with terminology/semantics matching 
the source document (e.g., medical chart) or what is observed in the real-world. 
Differences between countries need to be considered. Training using real-time dem-
onstration of electronic data collection (EDC) tool using examples of de-identified 
patient data is critical for chart reviews. For T&M studies, observers must be trained 
on accurate data measurement and recording. For a chart review using an EDC 
tool, logic and edit checks should be built into the EDC tool to limit data errors and 
incomplete data at entry. For a T&M design, speed of data transmission and fast 
quality control is essential to allow recall by the data observer. Queries for missing 
data or outliers should be phrased objectively and clearly. Effectiveness of quality 
control mechanisms needs to be assessed particularly at the start of data collection, 
and retraining performed, if needed. ConClusions: Limiting data collection errors 
and data incompleteness starts at study design. Essential components of a step-wise 
process include appropriate variable selection and description (terminology/seman-
tics), (re)training, and tailored quality control mechanisms. If such steps are fol-
lowed, data collected would result in a more accurate dataset, therefore improving 
the overall quality of study data and precision of study results.
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a coMPRehensIve dIsease Model of PolycystIc ovaRy syndRoMe (Pcos)
Eek D1, Paty J2, Black P3, Celeste Elash CA3, Reaney M4
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4ERT, Peterborough, UK
objeCtives: Polycystic ovary syndrome (PCOS) is one of the most common female 
endocrine disorders. It presents with a broad range of symptoms and has significant 
and diverse clinical implications. In order to develop a comprehensive understand-
ing of PCOS, a (conceptual) disease model was developed. Methods: The disease 
model was generated based on three lines of concept evaluation research; (1) a 
targeted literature review, (2) interviews with clinical experts; (3) concept elicita-
tion interviews with patients, for which data was recorded, transcribed and coded. 
Collectively, this provided a comprehensive list of the sign, symptom and impact 
concepts most important and relevant to women with PCOS. Results: Nineteen 
peer-reviewed articles were included in the literature review. Five clinical experts 
(USA, Turkey, Netherlands) and 20 PCOS patients (mean (SD) age 29.2 (5.9) years) were 
included in 1:1 qualitative interviews. Concept saturation was observed in patient 
interviews. Significant overlap was seen in the sign, symptom and impact concepts 
of PCOS across the three lines of evidence. Signs/symptoms were categorized into 
pain, infertility, hirsutism, alopecia, acne, menstruation (e.g. irregular menstrua-
tion, heavy bleeding), bloating, weight-related (e.g. weight gain, fluctuations), and 
metabolic abnormality (i.e., obesity, difficulty with weight loss, etc) symptoms. 
Some symptoms, such as pain at non-menstrual times, were uniquely reported 
by patients. Impacts of PCOS included sleep disturbance, emotional functioning, 
social role functioning and physical functioning. Compensatory behaviours (e.g. hair 
removal, diet changes, use of medication) were common. The relationship between 
these concepts is presented in a disease model. ConClusions: This is the first 
known comprehensive disease model for PCOS. It shows many of the defining fea-
tures of the condition can only be accurately and reliably captured by asking patients 
how they feel and function. This work underscores the need for measurement of 
PCOS from the patient perspective using a patient reported outcome (PRO).
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evaluatIon of QualIty assessMent tools foR non-RandoMIsed 
contRolled tRIals assessIng suRgIcal InteRventIons: a systeMatIc 
RevIew of systeMatIc RevIews
Nurmatov UB, Xiong T, Kroes MA
Abacus International, Bicester, UK
objeCtives: Evaluating the effectiveness and safety of surgical techniques, opera-
tions, and involved medical devices is relatively difficult, sometimes unethical, 
with randomised controlled trials (RCTs). Non-randomised designs are commonly 
applied and used to inform decision making. Quality assessment (QA) methods for 
these studies have previously been reviewed, but not specifically for their appli-
cability to non-RCTs in surgical interventions. The objectives of this systematic 
review were to evaluate which QA tools have been used in this research field and to 
critically appraise these tools. Methods: We systematically searched three elec-
tronic databases (MEDLINE, Embase and Cochrane Library) and Health Technology 
Assessments. Systematic reviews appraising the quality of non-RCTs on surgical 
interventions were included. Results: In total, 1,741 potentially relevant citations 
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targeted in this analysis. ConClusions: Prospective inclusion of health-economic 
endpoints in clinical trials for PAD is important to support future decision-making 
by payers and providers. The OPTIMIZE study collects targeted information on qual-
ity of life and resource utilization to facilitate future health-economic analyses.
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MethodologIcal consIdeRatIons foR the IMPleMentatIon of a 
euRoPean Mandated RetRosPectIve dRug utIlIsatIon study (dus) 
to InvestIgate the use of dexMedetoMIdIne (dexdoR®) In clInIcal 
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objeCtives: Dexmedetomidine was approved for ICU sedation in adults in the 
EU in 2011, but has been available in other countries since 1999 and used in many 
different clinical situations including in children. This study evaluated off-label 
use of dexmedetomidine in usual care in the EU. Methods: A chart review DUS 
of patients treated with dexmedetomidine was conducted in 16 hospitals across 
Austria, Finland, Germany and Poland. Patients were identified either prospectively 
or retrospectively, with anonymised data abstraction performed retrospectively 
post-administration. Chart data on patient demographics, indication, dexmedetomi-
dine administration, concomitant medications and therapeutic effectiveness were 
collected via an electronic data collection tool. Results: 2,000 patients received 
2,159 administrations of which 36.6% contained elements not according to the 
SmPC. Collecting off-label use was a concern to some sites and ethics committees, 
resulting in high site attrition and relatively slow start-up. Collecting sufficient 
mature dexmedetomidine use early after launch required focus on prolific users, 
while excluding regions where dexmedetomidine uptake was slow. Site selection 
was performed blinded by the Steering Committee to avoid bias. The study required 
collaboration across many hospital departments. Varied medical records systems 
required site-specific approaches to patient identification; some sites performing 
database searches, others using a manual process. Restricted access to records of 
patients from other hospital departments in some cases necessitated completion of 
paper worksheets by non-study hospital staff. Anonymised data collection avoided 
the need for informed consent but precluded patient verification and data queries, 
thus robust electronic data checks were essential. Data were regularly reviewed 
for evidence of duplication of patients within sites. ConClusions: Chart review 
DUS was successful in investigating off-label dexmedetomidine prescribing. Study 
conduct flexibility was essential to meet different needs of study sites and ensure 
study success. Close attention to potential sources of bias was required to ensure 
a robust outcome.
PRM233
tRIal desIgn and MaRket access IMPlIcatIons: outcoMes fRoM 
coMPaRatoR choIce
Khoury C1, Duque R1, Freiberg M2
1Quintiles Consulting, Neu-Isenburg, Germany, 2Quintiles Commercial, Mannheim, Germany
objeCtives: The choice of comparator drug is a critical factor in successful mar-
ket access, pricing and reimbursement by national payer bodies. Varying require-
ments specified for the comparator selected have led to approaches that differ by 
country. Legislation introduced in Germany in particular has affected studies in 
progress. As HTA agencies differ per country, the objective of the analysis which 
covers Germany, UK and France is twofold: - Do market access regulations influ-
ence trial design? - Do the chosen trial designs cover national pricing and reim-
bursement regulations? Methods: Published benefit assessments from selected 
HTA agencies websites such as G-BA, NICE and HAS were used to analyze diabetes 
drug assessments in terms of requested comparators and final recommendation. 
Furthermore, Clincialtrials.gov was used to analyze the trials in diabetes and their 
design. Results: Of the 49 HTA assessments by G-BA, HAS and NICE analyzed, 
10 assessments (20%) had an inappropriate comparator chosen. This resulted in 
eight negative recommendations, one positive with restrictions and one positive 
recommendation. Most of the HTA assessments with a positive outcome presented 
head-to-head or adjusted indirect comparisons. Unadjusted indirect comparisons 
were mainly rejected; and a mixed approach was allowed in France and England but 
not recommended in Germany. ConClusions: Having solely marketing authoriza-
tion (EMA) in mind when designing a trial can lead to an unsuccessful drug launch 
with regards to national pricing and reimbursement decisions. More specifically, 
the choice of comparator is considered as the most important factor for benefit 
assessment in Germany and the methodology applied is crucial to obtaining a posi-
tive outcome. In France and England, the use of specific guidelines for the choice 
of comparators and comparison methodology developed by NICE and validated by 
the HAS, is particularly relevant to obtain a positive outcome.
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the dIaBetes telePhone study: desIgn and challenges of a 
PRagMatIc clusteR RandoMIzed tRIal to IMPRove dIaBetIc PeRIPheRal 
neuRoPathy tReatMent
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objeCtives: Management of symptomatic diabetic peripheral neuropathy (DPN) 
is complicated by a lack of evidence regarding the comparative effectiveness of 
available agents, frequent side effects, and the need for ongoing symptom assess-
objeCtives: To compare trials of the four anti-epileptic drugs (AEDs) approved 
specifically for the adjunctive treatment of primary generalized tonic-clonic sei-
zures (PGTCS): topiramate [TPM] (1999), lamotrigine [LTG] (2006), levetiracetam [LEV] 
(2007), lamotrigine-XR [LTG-XR] (2010), and perampanel [PER] (2015). Methods: 
Trial data were identified through a systematic literature review. Main inclusion 
criteria: randomized, controlled, PGTCS with or without other generalized seizure 
types, and published 1989-2014. Key exclusion criteria: predominantly children/
adolescents and intravenous drug study. Data were abstracted from indexed pub-
lications, clinicaltrials.gov, and regulatory reports of the United States Food and 
Drug Administration and European Medicines Agency. Results: Five PGTCS trials 
[TPM-RCT (n= 80), LTG-RCT (n= 117), LEV-RCT (n= 164), LTG-XR-RCT (n= 146), PER-RCT 
(n= 163)] were identified. All trials were placebo-controlled where baseline AEDs 
were continued into the trial and consisted of the standard of care (SOC) at the time. 
Trial designs were similar with minor exceptions: PER-RCT allowed 1-3 baseline 
AEDs (others 1-2), LEV-RCT and PER-RCT had shorter titration periods (4 versus 7 & 8 
weeks), and LEV-RCT had the longest maintenance period (20 versus 12 & 13 weeks). 
Baseline PGTCS frequency was similar between trials except TPM-RCT which was 
higher (4.5-5.0 versus 2.3-3.0 per 28 days). The presence of LTG, LEV, and zonisamide 
in the SOC increased over time while the use of carbamazepine, phenytoin, and 
phenobarbital decreased. Valproate and TPM use fluctuated but appeared stable. In 
the latest phase III trial, PER-RCT had the following SOC composition, 43% valproate, 
39% LTG, 15% TPM, 31% LEV, 12% zonisamide, 8% carbamazepine, 6% phenytoin, and 
4% phenobarbital. ConClusions: Our review indicates that while the trial designs 
have remained similar over time, the SOC has evolved with the approval of new 
PGTCS medications. The latest trial, PER-RCT, has an SOC that is comprised heavily 
of the most recently approved PGTCS drugs.
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do we need to stRengthen study desIgn In oBseRvatIonal studIes?
Longagnani C, Simoni L, Fiori GG
Medineos Observational Research, Modena, Italy
objeCtives: Guidance and standards are made available by the European Network 
of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) as refer-
ence tools for methodology and transparency of post-authorization studies. They 
are cited by the Guideline on good pharmacovigilance practices (GVP) Module 
VIII as relevant scientific guidances. Here we report an analysis conducted on 
Pharmacovigilance Risk Assessment Committee (PRAC) minutes regarding meth-
odological issues. Methods: All publicly available minutes of PRAC meetings from 
July 2012 to March 2015 were considered. The number of submitted post-authoriza-
tion safety study (PASS) protocols requiring endorsement was recorded (excluding 
advices), as well as endorsement/ refusal and reason. ENCePP documentation was 
consulted. Results: From July 2012 to March 2015, 33 PASS protocols submitted to 
PRAC requiring endorsement were considered, increasing with years: 2 in 2012, 8 
(17 considering resubmissions) in 2013, 18 (24 considering resubmissions) in 2014. 
The total number of evaluations was 54. Thirteen were endorsed at the first step 
(including endorsement with changes requested), while 20 required at least one 
amendment reaching approval up to 15 months after submission. The most com-
mon reasons for refusal concerned study design (20 cases), mainly reporting designs 
not allowing to fulfil study objectives (N= 14). Furthermore, PRAC review asked for 
alternatives to reduce bias and confounding (N= 2), simplifications aiming at rein-
forcing the observational nature of the study (N= 1), further justification of sample 
size (N= 1) and considerations on feasibility (N= 1). From 2013 to 2014 an increasing 
number of endorsed PASS protocols was observed (7/17 and 12/24 respectively). 
During the same years ENCePP Checklist for Study Protocols and ENCePP Guide 
on Methodological Standards in Pharmacoepidemiology were reviewed, and the 
number of studies included in the ENCePP e-register increased. ConClusions: 
An increasing use of guidance and standards will allow strengthening robustness 
of design and results of observational studies.
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econoMIc study desIgn foR the oPtIMIze study on oRBItal 
atheRectoMy and dRug-coated Balloon devIces foR the tReatMent 
of Below-the-knee PeRIPheRal aRteRIal dIsease
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objeCtives: Present the economic study design of the OPTIMIZE study on orbital 
atherectomy system (OAS) and drug-coated balloon (DCB) treatment of peripheral 
artery disease (PAD) patients. Treating patients with calcified peripheral arterial 
lesions can be challenging and costly. The impact of OAS and DCBs in treating calci-
fied lesions has been studied independently. The objective of this study design is to 
assess the economic impact of treating below-the-knee (BTK) calcified PAD lesions 
with OAS+DCB compared to treating BTK calcified lesions with DCB alone (without 
OAS). Methods: This prospective, multi-center, post-market pilot study comparing 
OAS with adjunctive DCB angioplasty versus DCB angioplasty alone for treatment 
of calcified BTK lesions is a 1:1 randomized controlled study of 50 patients with 
calcification. In addition to clinical outcomes, health economic outcomes will be 
collected for the index procedure as well as additional procedures required during 
the clinical follow-up period. Results: Health economic outcomes will be meas-
ured at the index procedure, at 30 days, 3 months, 6 months, 12 months, and 24 
months post procedure for the treatment of PAD and its complications (repeat 
procedures, amputations, etc.). Health-related quality of life will be measured using 
the EQ-5D instrument. Resource utilization will be collected from case report forms 
and hospital accounting systems, using site-specific procedure code information 
of relevant OPS (German sites), CHOP (Swiss sites), and MEL codes (Austrian sites). 
Analyses from the third-party payer perspective will be informed by country-specific 
reimbursement amounts, using Germany as the initial reference case. Resulting cost 
difference and incremental cost-effectiveness are the main economic outcomes 
